Treatment of neoplasia
A method of treating cancer in a patient comprising administering to the patient an a systemic chemotherapeutic drug regime in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have an improved anticancer effect.
1. A method for treatment of a cancer patient in need of treatment, which comprises the steps of:
(i) delivering to said patient a treatment that lowers toxicity resulting from combining a radio-sensitizing agent oxaliplatin (OXA) with selective internal radiation therapy (SIRT), comprising on day one of a first chemotherapy treatment regime, comprising:
(a) a 2-hour infusion of oxaliplatin (OXA) at a dose of about 60 to 80 mg/m 2 ;
(b) a 2-hour infusion of leucovorin (LV) at a dose of about 100 to 400 mg/m 2 ;
(c) followed by a bolus of 5-fluorouracil (5-FU) at a dose of about 300 to 500 mg/m 2 and then an infusion of 5-FU for about 40 to 50 hours at a dose of about 2.0 to 2.6 g/m 2 ; and repeating step (i), if required, then
(ii) delivering selective internal radiation therapy (SIRT) to said patient between days 3 to 14 following either the commencement of step (i) or following the repeat of step (i);
(iii) repeating step (i) for three cycles at an interval of one to three weeks between treatment cycles; then
(iv) two weeks after the final treatment delivered in step (iii) delivering to said patient a second chemotherapy treatment regime, comprising:
(a) a 2-hour infusion of OXA at a dose of about 85 to 100 mg/m 2 ;
(b) a 2-hour infusion of LV at a dose of about 100 and 400 mg/m 2 ;
(c) followed by a bolus of 5-FU at a dose of about 300 to 500 mg/m 2 and then an infusion of 5-FU for about 40 to 50 hours at a dose of about 2.0 to 2.6 g/m 2 .
2. A method according to claim 1 further comprising the step of repeating step (iv) every 2 to 3 weeks, until the cancer is treated.
3. A method according to claim 1 , wherein the dose of OXA used in step (i)(a) is selected from one of the following OXA doses: 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 mg/m 2 .
4. A method according to claim 1 , wherein the dose of OXA used in step (iv)(a) is selected from one of the following OXA doses: 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 mg/m 2 .
5. A method according to claim 1 , wherein the dose of LV used in step (i)(b) or (iv)(b) is selected from one of the following LV doses: 100, 110, 120, 130, 140, 150, 160, 170, 180 and 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400 mg/m 2 .
6. A method according to claim 1 , wherein the bolus dose of 5-FU used in step (i)(c) or (iv)(c) is selected from one of the following 5-FU doses: 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500 mg/m 2 .
7. A method according to claim 1 , wherein the infusion dose of 5-FU used in step (i)(c) or (iv)(c) is selected from one of the following 5-FU doses: 2.1, 2.2, 2.3, 2.4 and 2.5 g/m 2 .
8. A method according to claim 1 , comprising the step of treating the patient with bevacizumab.
9. A method according to claim 8 wherein bevacizumab is administered at a dose of about 5 to 10 mg/kg.
10. A method according to claim 9 wherein the bevacizumab is delivered to a patient in 30 to 60 minutes.
11. A method according to claim 8 wherein the bevacizumab therapy is delivered to said patient in the last cycle of therapy immediately after OXA therapy.
12. A method according to claim 1 , wherein one or more chemotherapeutic agents additional to those used in the method are incorporated into systemic chemotherapy procedure drugs.
13. A method according claim 12 wherein the chemotherapeutic agents are selected from irinotecan or capecitabine.
14. A method according to claim 1 , wherein the patient is also treated with an anti-angiogenesis factor.
15. A method according to claim 1 , wherein the patient receives an amount of SIRT therapy suitable to effectively treat a cancer.
16. A method according to claim 1 , wherein the SIRT therapy is administered using SIR-Spheres™ microspheres.
17. A method according claim 16 wherein the prescribed activity of the SIR-Spheres™ microspheres in both lobes of the liver is between 1.2 and 2.4 GBq.
18. The method according to claim 1 , wherein step (iv) comprises two weeks after the final treatment is delivered in step (iii) a second chemotherapy treatment regime is delivered to said patient, wherein said second chemotherapy treatment regime comprises:
(a) a 2-hour infusion of OXA at a dose of about 85 to 100 mg/m 2 ;
(b) a 2-hour infusion of LV at a dose of about 100 and 400 mg/m 2 ;
(c) followed by a bolus of 5-FU at a dose of about 300 to 500 mg/m 2 and a 15 to 90 minute infusion of bevacizumab at about 5 to 15 mg/kg, followed by an infusion of 5-FU for about 40 to 50 hours at a dose of about 2.0 to 2.6 g/m 2 .